This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Isocitrate dehydrogenase 1 mutation drives leukemogenesis by PDGFRA activation due to insulator disruption in acute myeloid leukemia (AML)
Leukemia Open Access 21 November 2022
-
Different methylation signatures at diagnosis in patients with high-risk myelodysplastic syndromes and secondary acute myeloid leukemia predict azacitidine response and longer survival
Clinical Epigenetics Open Access 14 January 2021
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Fenaux P, Mufti GJ, Hellström-Lindberg E, Santini V, Finelli C, Giagounidis A et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomized, open-label, phase III study. Lancet Oncol 2009; 10: 223–232.
Fenaux P, Gattermann N, Seymour JF, Hellström-Lindberg E, Mufti GJ, Duehrsen U et al. Prolonged survival with improved tolerability in higher-risk myelodysplastic syndromes: azacitidine compared with low-dose ara-C. Br J Haematol 2010; 149: 244–249.
Flotho C, Claus R, Batz C, Schneider M, Sandrock I, Ihde S et al. The DNA methyltransferase inhibitors azacitidine, decitabine and zebularine exert differential effects on cancer gene expression in acute meloid leukemia cells. Leukemia 2009; 23: 1019–1028.
Curik N, Burda P, Vargova K, Pospisil V, Belickova M, Vlckova P et al. 5-Azacitidine in aggressive myelodysplastic syndromes regulates chromatin structure at PU.1 and cell differentiation capacity. Leukemia 2012; 26: 1804–1811.
Schmeltz K, Sattler N, Wagner M, Lübbert M, Tamm I . Induction of gene expression by 5-Aza-2’-deoxycitidine in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) but not epithelial cells by DNA-methylation dependent and –independent mechanisms. Leukemia 2005; 19: 103–111.
Khan R, Schmidt-Mende J, Karimi M, Gogvadze V, Hassan M, Ekström TJ et al. Hypomethylation and apoptosis in 5-azacytidine-treated myeloid cells. Exp Hematol 2008; 36: 149–157.
Sánchez-Abarca LI, Gutierrez-Cosio S, Santamaría C, Caballero-Velazquez T, Blanco B, Herrero-Sánchez C et al. Immunomodulatory effect of 5-azacytidine (5-azaC): potential role in the transplantation setting. Blood 2010; 115: 107–121.
Komashko VM, Farnham PJ . 5-azacytidine treatment reorganizes genomic histone modification patterns. Epigenetics 2010; 5: 229–240.
Schaefer M, Hagemann S, Hanna K, Lyko K . Azacytidine inhibits RNA methylation at DNMT2 target sites in human cancer cell lines. Cancer Res 2009; 69: 8127–8132.
Grövdal M, Karimi M, Khan R, Aggerholm A, Antunovic P, Astermark J et al. Maintenance treatment with azacitidine for patients with high-risk myelodysplastic syndromes (MDS) or acute myeloid leukemia following MDS in complete remission after induction chemotherapy. Br J Haematol 2010; 150: 293–302.
Yang AS, Doshi KD, Choi SW, Mason JB, Mannari RK, Gharybian V et al. DNA methylation changes after 5-aza-2’-deoxycytidine therapy in patients with leukemia. Cancer Res 2006; 66: 5495–5503.
Aparicio A, North B, Barske L, Wang X, Bollati V, Weisenberger D et al. LINE-1 methylation is plasma DNA as a biomarker of activity of DNA methylation inhibition in patients with solid tumors. Epigenetics 2009; 4: 20–28.
Figueroa ME, Skrabanek L, Li Y, Fandy TE, Paietta E, Fernandez H et al. MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation. Blood 2009; 114: 3448–3458.
Hon GC, Hawkins RD, Caballero OL, Lo C, Lister R, Pelizzola M et al. Global DNA hypomethylation coupled to repressive chromatin domain formation and gene silencing in breast cancer. Genome Res 2011; 22: 246–258.
Romano A, Barresi V, Capizzi C, Giallongo C, Nicolo M, La Cava P et al. Proteomic and genomic profile of high-risk MDS after treatment with 5-azacitidine. ASH annual meeting abstracts Blood 2011; 118: 3818.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Additional information
Supplementary Information accompanies this paper on the Leukemia website
Supplementary information
Rights and permissions
About this article
Cite this article
Grövdal, M., Karimi, M., Tobiasson, M. et al. Azacitidine induces profound genome-wide hypomethylation in primary myelodysplastic bone marrow cultures but may also reduce histone acetylation. Leukemia 28, 411–413 (2014). https://doi.org/10.1038/leu.2013.265
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2013.265